Figure 2 - Prevalence of comorobid diseases in patients with COVID-19 stratified by asthma status

-  It was noted that there was a significant increase in patients with additional comorbidities, asthma, and COVID-19 proportionately
- These comorbidities include, but were not limited to obesity, hypertension, sleep apnea, diabetes, etc.
- These values are presented in a more visual format in Figure 2


Ohio State University, Columbus

- This paper details the interactions f asthma and COVID-19 in the United States
- Due to limited data, it is difficult to pinpoint whether asthma puts someone at an increased risk for COVID-19 infection
- This study looks to determine the prevalence of asthma and asthma related comorbidities and COVID-19 as well as generally evaluate the hospitalization rates of COVID-19 patients with and without asthma
- Though most of the data for this study was able to be automated, to confirm asthma diagnoses in COVID-19 patients, all automatically flagged asthma charts in the database were manually checked as well
- It was generally found that out of the 1526 patients whose criteria met study guidelines, 14.4% (220) had asthma
- The prime demographic for asthma and COVID-19 was the 40-69 year old group (55.3%), and the predominant sub group of this was patients who claimed to be non-Hispanic African American (35.5%)
- Platelet count in non-asthmatic patients was significantly lower than those with asthma
- Lab values taken during the study indicate that patients with asthma and COVID-19 had significantly lower levels of ferritin, C-reactive protein, and lactate dehydrogenase

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19 (United States)

Chhiba, K. D., Patel, G. B., Vu, T., Chen, M. M., Guo, A., Kudlaty, E., Mai, Q., Yeh, C., Muhammad, L. N., Harris, K. E., Bochner, B. S., Grammer, L. C., Greenberger, P. A., Kalhan, R., Kuang, F. L., Saltoun, C. A., Schleimer, R. P., Stevens, W. W., & Peters, A. T. (2020). Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. The Journal of allergy and clinical immunology, 146(2), 307–314.e4. https://doi.org/10.1016/j.jaci.2020.06.010

URL: https://pubmed.ncbi.nlm.nih.gov/32554082/

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

- Through analyzing the data by adjusting for baseline age, sex, and race, it was found that asthma and COVID-19 comorbid patients were not at increased risk of hospitalization
- This was analysis was furthered by tailoring to other patient factors, such as smoking or other comorbidities and it was still found that there was no increased risk for hospitalization
- It was found that regardless of asthmatic status or data constraints, Hispanics offered a higher hospitalization rate than other races


Discussion Regarding Hospitalization of Patients with Asthma and COVID-19

Discussion Regarding Additional Comorbidities of Patients with Asthma and COVID-19

- More than half of asthmatics (52%, 114 patients) at time of diagnosis were not prescribed inhaled corticosteroids or a long acting beta agonist inhaled corticosteroid regimen
- It was noted that in groups of patients who required outpatient or non-ICU inpatient care, asthmatics who were not prescribed an ICS or LABA/ICS were the highest
- Subsequently, the group with the highest amount of inpatient ICU requiring patients were the group on a LABA/ICS regimen
- At time of diagnosis, 15 asthmatic patients had been receiving oral steroids and 13 patients from this subset were prescribed prednisone bursts in response to an asthma exacerbation in the 2 weeks prior to COVID-19 diagnosis


Learn Before

Related

Learn After